Jon Napitupulu

Werewolf Therapeutics has begun a strategic alternatives process, retaining Piper Sandler to evaluate options that include a sale, merger,...

Leonabio has acquired an exclusive global license (excluding Asia and select Middle Eastern countries) to develop and commercialize lasofoxifene,...

DBV Technologies closed 2025 with momentum behind its Viaskin Peanut program, reporting positive phase 3 results in children aged...

Rani Therapeutics has moved its oral biologics platform from promise to clinical testing, initiating a Phase 1 study of...

Spero Therapeutics’ partner GSK has resubmitted the New Drug Application for tebipenem HBr, an oral carbapenem for complicated urinary...

Kyverna Therapeutics is moving to file a BLA in the first half of 2026 for miv-cel (mivocabtagene autoleucel, KYV-101)...

Inhibikase Therapeutics has initiated IMPROVE-PAH, a global, adaptive pivotal Phase 3 program of IKT-001 in pulmonary arterial hypertension, with...

Zenas BioPharma has launched concurrent underwritten offerings of convertible senior notes due 2032 and common stock, including 30-day overallotment...

MoonLake Immunotherapeutics reported Week 40 results from its twin Phase 3 VELA trials of sonelokimab in moderate-to-severe hidradenitis suppurativa,...

Cue Biopharma has appointed Lucinda Warren as interim president and chief executive officer, effective March 26, 2026, following the...